FMP

FMP

Enter

HEPA - Hepion Pharmaceutica...

Financial Summary of Hepion Pharmaceuticals, Inc.(HEPA), Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therap

photo-url-https://financialmodelingprep.com/image-stock/HEPA.png

Hepion Pharmaceuticals, Inc.

HEPA

NASDAQ

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

2.19 USD

-0.08 (-3.65%)

About

ceo

Mr. John T. Cavan

sector

Healthcare

industry

Biotechnology

website

https://www.hepionpharma.com

exchange

NASDAQ

Description

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The co...

CIK

0001583771

ISIN

US4268973025

CUSIP

426897104

Address

399 Thornall Street

Phone

732 902 4000

Country

US

Employee

25

IPO Date

Feb 10, 2014

Summary

CIK

0001583771

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

426897104

ISIN

US4268973025

Country

US

Price

2.19

Beta

1.62

Volume Avg.

77.72k

Market Cap

9.5M

Shares

-

52-Week

1.49-20.66

DCF

0.67

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.18

P/B

-

Website

https://www.hepionpharma.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest HEPA News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep